160 related articles for article (PubMed ID: 17338934)
1. Combination therapy and new types of agents for pulmonary arterial hypertension.
O'Callaghan DS; Gaine SP
Clin Chest Med; 2007 Mar; 28(1):169-85, ix. PubMed ID: 17338934
[TBL] [Abstract][Full Text] [Related]
2. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
[TBL] [Abstract][Full Text] [Related]
3. Combination drug therapy in the management of pulmonary arterial hypertension.
Kayser SR
Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142
[No Abstract] [Full Text] [Related]
4. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
5. Treatments for pulmonary arterial hypertension.
Liu C; Liu K; Ji Z; Liu G
Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary arterial hypertension: combination therapy in the modern management era.
Sitbon O
Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
[No Abstract] [Full Text] [Related]
7. Treatment of pulmonary arterial hypertension.
Humbert M; Sitbon O; Simonneau G
N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304
[No Abstract] [Full Text] [Related]
8. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
9. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
[TBL] [Abstract][Full Text] [Related]
10. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
11. Management of pulmonary arterial hypertension with a focus on combination therapies.
Benza RL; Park MH; Keogh A; Girgis RE
J Heart Lung Transplant; 2007 May; 26(5):437-46. PubMed ID: 17449411
[TBL] [Abstract][Full Text] [Related]
12. Bosentan for the treatment of portopulmonary hypertension.
Tempe DK; Datt V; Datta D
Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
[No Abstract] [Full Text] [Related]
13. Idiopathic pulmonary arterial hypertension.
Souza R; Jardim C; Humbert M
Semin Respir Crit Care Med; 2013 Oct; 34(5):560-7. PubMed ID: 24037625
[TBL] [Abstract][Full Text] [Related]
14. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatment for pulmonary arterial hypertension.
Sastry BK
Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
17. [Combination therapy in patients with pulmonary arterial hypertension].
Ewert R; Opitz CF; Schäper C; Gläser S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
[TBL] [Abstract][Full Text] [Related]
18. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
19. Emerging medical therapies for pulmonary arterial hypertension.
Galiè N; Manes A; Branzi A
Prog Cardiovasc Dis; 2002; 45(3):213-24. PubMed ID: 12525997
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
